Total Payments
$9,194
2024 Payments
$1,600
Companies
51
Transactions
547
Medicare Patients
4,923
Medicare Billing
$668,188
Payment Breakdown by Category
Food & Beverage$9,086 (98.8%)
Research$61.00 (0.7%)
Education$46.50 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,086 | 542 | 98.8% |
| Unspecified | $61.00 | 1 | 0.7% |
| Education | $46.50 | 4 | 0.5% |
Payments by Type
General
$9,133
546 transactions
Research
$61.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $858.84 | 52 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $830.62 | 60 | $0 (2024) |
| PFIZER INC. | $698.75 | 64 | $0 (2024) |
| Janssen Biotech, Inc. | $615.19 | 46 | $0 (2024) |
| Amgen Inc. | $469.82 | 41 | $0 (2020) |
| Merck Sharp & Dohme LLC | $438.49 | 27 | $0 (2024) |
| Astellas Pharma US Inc | $411.86 | 19 | $0 (2022) |
| GENZYME CORPORATION | $397.52 | 17 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $363.63 | 21 | $0 (2024) |
| Celgene Corporation | $360.75 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,600 | 66 | PFIZER INC. ($264.42) |
| 2023 | $908.36 | 36 | Celgene Corporation ($156.13) |
| 2022 | $699.41 | 25 | Kite Pharma, Inc. ($134.82) |
| 2021 | $122.97 | 6 | Novartis Pharmaceuticals Corporation ($34.96) |
| 2020 | $501.43 | 31 | Janssen Biotech, Inc. ($51.41) |
| 2019 | $2,050 | 129 | Astellas Pharma US Inc ($231.23) |
| 2018 | $2,125 | 151 | E.R. Squibb & Sons, L.L.C. ($486.95) |
| 2017 | $1,187 | 103 | Novartis Pharmaceuticals Corporation ($169.60) |
All Payment Transactions
547 individual payment records from CMS Open Payments — Page 2 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $27.88 | General |
| Category: Oncology | ||||||
| 08/21/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: Oncology | ||||||
| 08/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.11 | General |
| Category: Oncology | ||||||
| 08/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: Oncology | ||||||
| 08/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.13 | General |
| Category: Oncology | ||||||
| 08/05/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $1.55 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/30/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | VPRIV (Biological) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: GENETIC DISEASE | ||||||
| 07/12/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Oncology | ||||||
| 06/22/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: ONCOLOGY | ||||||
| 06/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: Rare Disease | ||||||
| 06/08/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: ONCOLOGY | ||||||
| 06/07/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $0.82 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $25.84 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.37 | General |
| Category: Oncology | ||||||
| 05/24/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $32.90 | General |
| Category: Oncology | ||||||
| 05/17/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $0.84 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.74 | General |
| Category: Hematology/Oncology | ||||||
| 05/06/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $21.07 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma | ABBVIE INC. | $61.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 1,191 | 2,008 | $529,528 | $164,979 |
| 2022 | 7 | 1,151 | 2,129 | $567,564 | $174,072 |
| 2021 | 8 | 1,201 | 2,047 | $540,058 | $170,159 |
| 2020 | 9 | 1,380 | 2,310 | $533,598 | $158,978 |
Total Patients
4,923
Total Services
8,494
Medicare Billing
$668,188
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 305 | 673 | $176,978 | $51,913 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 206 | 435 | $114,412 | $32,905 | 28.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 106 | 215 | $53,179 | $21,099 | 39.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 121 | 123 | $44,229 | $17,361 | 39.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 93 | 93 | $32,059 | $9,565 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 112 | 164 | $30,475 | $7,923 | 26.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 38 | 53 | $19,488 | $5,894 | 30.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 57 | 57 | $19,647 | $5,760 | 29.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 77 | 100 | $18,598 | $5,113 | 27.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 55 | 71 | $11,619 | $4,702 | 40.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 24 | $8,844 | $2,744 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 291 | 727 | $194,176 | $54,864 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 173 | 379 | $101,207 | $28,719 | 28.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 93 | 239 | $50,969 | $20,314 | 39.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 104 | 107 | $44,294 | $17,129 | 38.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 58 | 117 | $44,320 | $13,318 | 30.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 138 | 199 | $37,862 | $10,536 | 27.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 90 | 90 | $31,821 | $9,415 | 29.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 76 | 107 | $20,347 | $5,653 | 27.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 27 | 39 | $14,774 | $4,824 | 32.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 56 | 80 | $11,885 | $4,724 | 39.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 45 | 45 | $15,910 | $4,577 | 28.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 268 | 588 | $159,130 | $47,198 | 29.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 167 | 328 | $88,776 | $26,047 | 29.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 86 | 150 | $56,653 | $18,168 | 32.1% |
About Dr. Liat Dagan, MD
Dr. Liat Dagan, MD is a Hematology & Oncology healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1518167451.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Liat Dagan, MD has received a total of $9,194 in payments from pharmaceutical and medical device companies, with $1,600 received in 2024. These payments were reported across 547 transactions from 51 companies. The most common payment nature is "Food and Beverage" ($9,086).
As a Medicare-enrolled provider, Dagan has provided services to 4,923 Medicare beneficiaries, totaling 8,494 services with total Medicare billing of $668,188. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Boca Raton, FL
- Active Since 07/19/2007
- Last Updated 02/16/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1518167451
Products in Payments
- OPDIVO (Biological) $476.48
- KEYTRUDA (Biological) $399.65
- Erleada (Drug) $294.27
- XOSPATA (Drug) $231.23
- EMPLICITI (Biological) $175.04
- JAKAFI (Drug) $171.95
- ELIQUIS (Drug) $167.67
- TIBSOVO (Drug) $165.10
- ADCETRIS (Biological) $165.02
- IMBRUVICA (Drug) $159.98
- LYNPARZA (Drug) $155.85
- Neulasta (Biological) $155.56
- Yescarta (Drug) $146.83
- IBRANCE (Drug) $145.64
- MEKINIST (Drug) $139.51
- PROMACTA (Drug) $137.29
- KISQALI (Drug) $128.94
- Nplate (Biological) $127.47
- Venclexta (Drug) $124.57
- SOMATULINE DEPOT (Drug) $115.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boca Raton
Mohammad Jahanzeb, Md, MD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Fernando Recio, Md, MD
Hematology & Oncology — Payments: $26,134
Hematology & Oncology $26,134
Dr. Paul Hyman, Md, MD
Hematology & Oncology — Payments: $9,103
Hematology & Oncology $9,103
Dr. Bachir Berbari, Md, MD
Hematology & Oncology — Payments: $6,995
Hematology & Oncology $6,995
Dr. Steven Morris, M.d, M.D
Hematology & Oncology — Payments: $6,937
Hematology & Oncology $6,937
Dr. Aurea Tomeski, M.d, M.D
Hematology & Oncology — Payments: $22.15
Hematology & Oncology $22.15